» Articles » PMID: 19843089

Human Papillomavirus 16-specific T Cell Responses in Classic HPV-related Vulvar Intra-epithelial Neoplasia. Determination of Strongly Immunogenic Regions from E6 and E7 Proteins

Overview
Date 2009 Oct 22
PMID 19843089
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Cell-mediated immunity directed against human papillomavirus 16 (HPV-16) antigens was studied in 16 patients affected with classic vulvar intra-epithelial neoplasia (VIN), also known as bowenoid papulosis (BP). Ten patients had blood lymphocyte proliferative T cell responses directed against E6/2 (14-34) and/or E6/4 (45-68) peptides, which were identified in the present study as immunodominant among HPV-16 E6 and E7 large peptides. Ex vivo enzyme-linked immunospot-interferon (IFN)-gamma assay was positive in three patients who had proliferative responses. Twelve months later, proliferative T cell responses remained detectable in only six women and the immunodominant antigens remained the E6/2 (14-34) and E6/4 (45-68) peptides. The latter large fragments of peptides contained many epitopes able to bind to at least seven human leucocyte antigen (HLA) class I molecules and were strong binders to seven HLA-DR class II molecules. In order to build a therapeutic anti-HPV-16 vaccine, E6/2 (14-34) and E6/4 (45-68) fragments thus appear to be good candidates to increase HPV-specific effector T lymphocyte responses and clear classic VIN (BP) disease lesions.

Citing Articles

Genetic variations in human papillomavirus and cervical cancer outcomes.

Rader J, Tsaih S, Fullin D, Murray M, Iden M, Zimmermann M Int J Cancer. 2018; 144(9):2206-2214.

PMID: 30515767 PMC: 6450540. DOI: 10.1002/ijc.32038.


Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Ramos C, Narala N, Vyas G, Leen A, Gerdemann U, Sturgis E J Immunother. 2012; 36(1):66-76.

PMID: 23211628 PMC: 3521877. DOI: 10.1097/CJI.0b013e318279652e.


Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners.

Jacobelli S, Sanaa F, Moyal-Barracco M, Pelisse M, Berville S, Villefroy P PLoS One. 2012; 7(5):e36651.

PMID: 22590583 PMC: 3348873. DOI: 10.1371/journal.pone.0036651.

References
1.
Arany I, Tyring S . Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res. 1996; 16(6):453-60. DOI: 10.1089/jir.1996.16.453. View

2.
Ressing M, Sette A, BRANDT R, Ruppert J, Wentworth P, Hartman M . Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol. 1995; 154(11):5934-43. View

3.
Tsukui T, Hildesheim A, Schiffman M, Lucci 3rd J, Contois D, Lawler P . Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res. 1996; 56(17):3967-74. View

4.
Kadish A, Timmins P, Wang Y, Ho G, Burk R, Ketz J . Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 2002; 11(5):483-8. View

5.
Arany I, Tyring S . Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. Sex Transm Dis. 1996; 23(6):475-80. DOI: 10.1097/00007435-199611000-00007. View